Intravenous ciprofloxacin versus erythromycin in the treatment of Legionella pneumonia

Internal Medicine

Volumn 46, Issue 7, 2007, Pages 353-357

  Haranaga, Shusaku ^a   Tateyama, Masao ^a   Higa, Futoshi ^a   Miyagi, Kazuya ^a   Akamine, Morikazu ^a   Azuma, Masato ^a   Yara, Satomi ^a   Koide, Michio ^a   Fujita, Jiro ^a  

^a UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Ciprofloxacin; Erythromycin; Legionella pneumonia

Indexed keywords

C REACTIVE PROTEIN; CIPROFLOXACIN; ERYTHROMYCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE TECHNIQUE; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; FEMALE; GENDER; HUMAN; IMMUNOASSAY; LEGIONELLA; LEGIONNAIRE DISEASE; LEUKOCYTOSIS; MALE; PNEUMONIA; POLYMERASE CHAIN REACTION; SEROLOGY; TREATMENT DURATION; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CIPROFLOXACIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ERYTHROMYCIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; JAPAN; LEGIONNAIRES' DISEASE; MALE; MIDDLE AGED; PROBABILITY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 34247171368     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.46.6006     Document Type: Article

References (15)

1. Edelstein PH. Antimicrobial chemotherapy for Legionnaires' disease: time for a change. Ann Intern Med 129: 328-330, 1998.
2. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37: 1405-1433, 2003.
3. Haranaga S, Toyama M, Arakaki N, et al. Legionella pneumophila pneumonia successfully treated with intravenous ciprofloxacin. Intern Med 41: 1024-1028, 2002.
4. Tsukadaira A, Okubo Y, Takashi S, et al. An infection with Legionella pneumophila treated with intravenous ciprofloxacin. Nihon Kokyuki Gakkai Zasshi 40: 245-248, 2002 (in Japanese, abstract in English).
5. Sabria M, Pedro-Botet ML, Gomez J, et al. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 128: 1401-1405, 2005.
6. Blazquez Garrido RM, Espinosa Parra FJ, Alemany Frances L, et al. Antimicrobial chemotheraphy for legionnaires disease: levoflocxacin versus macrolides. Clin Infect Dis 40: 800-806, 2005.
7. The committee for the Japanese Respiratory Society guidelines in the management of respiratory infections. The JRS guidelines for the management of community-acquired pneumonia in adults. The Japanese Respiratory Society 2005 (in Japanese).
8. Bartlett JG, Brieman RF, Mandell LA, et al. Community acquired pneumonia in adults: Guidelines for management. Clin Infect Dis 26: 811-836, 1988.
9. Easmon CS, Crane JP. Uptake of ciprofloxacin by human neutrophils. J Antimicrob Chemother 16: 67-73, 1985.
10. Dan M, Torossian K, Weissberg D, et al. The penetration of ciprofloxacin into bronchial mucosa, lung parenchyma, and pleural tissue after intravenous administration. Eur J Clin Pharmacol 44: 101-102, 1993.
11. Unertl KE, Lenhart FP, Forst H, et al. Ciprofloxacin in the treatment of legionellosis in critically ill patients including those cases unresponsive to erythromycin. Am J Med 87: 128S-131S, 1989.
12. Hooper TL, Gould FK, Swinburn CR, et al. Ciprofloxacin: a preferred treatment for legionella infections in patients receiving cyclosporine A. J Antimicrob Chemother 22: 952-953, 1988.
13. Higa F, Shinzato T, Toyama M, et al. Efficacy of pazufloxacin mesilate in Legionnaires' disease: a case report and in vitro study of the isolate. J Infect Chemother 11: 164-168, 2005.
14. Kurz RW, Grainger W, Egger TP, Pichler H, Tragl KH. Failure of treatment of Leggionella pneumonia with ciprofloxacin. J Antimicrobiol Chemother 22: 389-391, 1988.
15. Martin SJ, Pendland SL, Chen C, et al. In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella. Antimicrob Agents Chemother 40: 1419-1421, 1996.